AV-951 is an potent and selective orally bioavailable isoxazole inhibitor of VEGFR1, 2, and 3, kinases at 0.21, 0.16, and 0.24 nM, respectively. Additionally it has nanomolar activity for cKIT and PDGFR at 1.63 and 1.72 nM, respectively. [1] In vitro, AV-951 blocks MAP kinase activation and suppresses the proliferation and migration of endothelial cells. In vivo, it suppresses angiogenesis and tumor progression in human xenografts. [2]AV-951 has been widely studied in clinical trials for the treatment of advanced renal cell carcinoma (RCC) and non-small cell lung cancers (NSCLC). More recent studies are exploring combination therapies with paclitaxel and bevacizumab for breast and colorectal cancer, respectively.

Technical information:

Shipping Condition: The product is shipped in a glass vial at ambient temperature.Storage condition: For longer shelf life, store solid powder at 4^oC desiccated, or store DMSO solution at -20^oC.

Reference:

Other Information:

Product Specification (pdf) MSDS (pdf) Certificate of Analysis is available upon request.

Cellagen利用广泛的研究以及我们在干细胞生物学，药物化学和产品开发方面的专业知识，Cellagen长期以来一直为专业OEM产品提供世界领先的公司，为一线干细胞研究奠定了基础。

现在，Cellagen扩展了其最佳产品系列，并直接向研究界提供。Cellagen与世界领先的科学家有着密切的联系，并且始终认识到高标准科学研究的未满足需求。